FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285403714> ?p ?o ?g. }

• W4285403714 endingPage "e772" @default.
• W4285403714 startingPage "e764" @default.
• W4285403714 abstract "The development of brain metastases occurs commonly in HER2-positive metastatic breast cancer and is associated with a poorer prognosis. The advent of HER2-targeted therapy has improved overall survival, but the benefit in patients with brain metastases is unclear, as these patients are often excluded from clinical trials. This study aimed to explore real-world outcomes in patients with brain metastases in HER2-positive MBC.Data was extracted from the TABITHA registry, which consists of patient data collected prospectively from 16 Australian sites from 24th February 2015 to 31st October 2021. Data analysed included characteristics of brain metastases, treatment received and survival outcomes.A total of 135 (37%) of 361 patients with HER2-positive MBC were diagnosed with brain metastases during their clinical course, including 45 (12%) with brain metastases at time of MBC diagnosis. 61 (45%) had ≥4 brain lesions. The most common local therapy given was whole brain radiation therapy (WBRT) (36%) followed by multi-modality treatment with both surgery and radiation therapy (27%). The majority of patients received first-line HER2-targeted treatment with trastuzumab and pertuzumab followed by second-line trastuzumab emtansine (T-DM1) but third-line therapy was heterogenous. The median overall survival in patients who developed brain metastases was significantly shorter than those who did not develop brain metastases (58.9 vs. 96.1 months, P = .02).Real-world patients diagnosed with brain metastases in HER2-positive MBC have a relatively poor prognosis, despite advances in HER2-targeted treatment. As the range of HER2-targeted treatment expands, it is important to pursue clinical trials that focus on patients with brain metastases." @default.
• W4285403714 created "2022-07-14" @default.
• W4285403714 creator A5001134809 @default.
• W4285403714 creator A5003588327 @default.
• W4285403714 creator A5008937610 @default.
• W4285403714 creator A5011046495 @default.
• W4285403714 creator A5012424242 @default.
• W4285403714 creator A5012510777 @default.
• W4285403714 creator A5020653949 @default.
• W4285403714 creator A5029043252 @default.
• W4285403714 creator A5032945961 @default.
• W4285403714 creator A5041233223 @default.
• W4285403714 creator A5047478386 @default.
• W4285403714 creator A5052521608 @default.
• W4285403714 creator A5058474941 @default.
• W4285403714 creator A5059673131 @default.
• W4285403714 creator A5067802897 @default.
• W4285403714 creator A5082250344 @default.
• W4285403714 creator A5086080884 @default.
• W4285403714 date "2022-10-01" @default.
• W4285403714 modified "2023-09-28" @default.
• W4285403714 title "Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study" @default.
• W4285403714 cites W1976628810 @default.
• W4285403714 cites W2053465841 @default.
• W4285403714 cites W2111718329 @default.
• W4285403714 cites W2125401809 @default.
• W4285403714 cites W2127714076 @default.
• W4285403714 cites W2130735457 @default.
• W4285403714 cites W2143843774 @default.
• W4285403714 cites W2150408445 @default.
• W4285403714 cites W2159967578 @default.
• W4285403714 cites W2318605753 @default.
• W4285403714 cites W2404207385 @default.
• W4285403714 cites W2475512188 @default.
• W4285403714 cites W2492450141 @default.
• W4285403714 cites W2580983429 @default.
• W4285403714 cites W2595711623 @default.
• W4285403714 cites W2616596696 @default.
• W4285403714 cites W2887919639 @default.
• W4285403714 cites W2907345836 @default.
• W4285403714 cites W2937747054 @default.
• W4285403714 cites W2949170515 @default.
• W4285403714 cites W2962460569 @default.
• W4285403714 cites W2994671294 @default.
• W4285403714 cites W2996630100 @default.
• W4285403714 cites W3005704292 @default.
• W4285403714 cites W3012380787 @default.
• W4285403714 cites W3014908000 @default.
• W4285403714 cites W3026270620 @default.
• W4285403714 cites W3030461309 @default.
• W4285403714 cites W3092045910 @default.
• W4285403714 cites W3197573824 @default.
• W4285403714 cites W3207557929 @default.
• W4285403714 cites W4206666777 @default.
• W4285403714 doi "https://doi.org/10.1016/j.clbc.2022.07.005" @default.
• W4285403714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35941066" @default.
• W4285403714 hasPublicationYear "2022" @default.
• W4285403714 type Work @default.
• W4285403714 citedByCount "0" @default.
• W4285403714 crossrefType "journal-article" @default.
• W4285403714 hasAuthorship W4285403714A5001134809 @default.
• W4285403714 hasAuthorship W4285403714A5003588327 @default.
• W4285403714 hasAuthorship W4285403714A5008937610 @default.
• W4285403714 hasAuthorship W4285403714A5011046495 @default.
• W4285403714 hasAuthorship W4285403714A5012424242 @default.
• W4285403714 hasAuthorship W4285403714A5012510777 @default.
• W4285403714 hasAuthorship W4285403714A5020653949 @default.
• W4285403714 hasAuthorship W4285403714A5029043252 @default.
• W4285403714 hasAuthorship W4285403714A5032945961 @default.
• W4285403714 hasAuthorship W4285403714A5041233223 @default.
• W4285403714 hasAuthorship W4285403714A5047478386 @default.
• W4285403714 hasAuthorship W4285403714A5052521608 @default.
• W4285403714 hasAuthorship W4285403714A5058474941 @default.
• W4285403714 hasAuthorship W4285403714A5059673131 @default.
• W4285403714 hasAuthorship W4285403714A5067802897 @default.
• W4285403714 hasAuthorship W4285403714A5082250344 @default.
• W4285403714 hasAuthorship W4285403714A5086080884 @default.
• W4285403714 hasConcept C121608353 @default.
• W4285403714 hasConcept C126322002 @default.
• W4285403714 hasConcept C143998085 @default.
• W4285403714 hasConcept C185926286 @default.
• W4285403714 hasConcept C2775930923 @default.
• W4285403714 hasConcept C2777329042 @default.
• W4285403714 hasConcept C2778087150 @default.
• W4285403714 hasConcept C2778164965 @default.
• W4285403714 hasConcept C2779013556 @default.
• W4285403714 hasConcept C2779786085 @default.
• W4285403714 hasConcept C2781164504 @default.
• W4285403714 hasConcept C2781230642 @default.
• W4285403714 hasConcept C509974204 @default.
• W4285403714 hasConcept C530470458 @default.
• W4285403714 hasConcept C71924100 @default.
• W4285403714 hasConceptScore W4285403714C121608353 @default.
• W4285403714 hasConceptScore W4285403714C126322002 @default.
• W4285403714 hasConceptScore W4285403714C143998085 @default.
• W4285403714 hasConceptScore W4285403714C185926286 @default.
• W4285403714 hasConceptScore W4285403714C2775930923 @default.
• W4285403714 hasConceptScore W4285403714C2777329042 @default.

• next